Home/ Stocks/ BEAM

Beam Therapeutics Inc. Common Stock

BEAM XNAS

$27.48 -0.06 (-0.22%) ▼ 15-min delayed

Open

$27.71

High

$28.35

Low

$27.13

Volume

1.32M

Market Cap

$2.81B

About Beam Therapeutics Inc. Common Stock

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.

Sector: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Employees: 522 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q2 2026	$490.0K	$-122,678,000	$-1.18
Q1 2026	$31.74M	$-94,318,000	$-0.91
FY 2025	$139.74M	$-79,992,000	$-0.81
Q3 2025	$9.70M	$-112,728,000	$-1.10

Earnings & Analyst Ratings

Next Earnings: Mon, Nov 2, 2026

Calendar →

Related Market News

No specific coverage for BEAM yet. Check out our latest market news or earnings calendar.

Get BEAM Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Beam Therapeutics Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.